Asahi Kasei Pharma Obtains All Intellectual Property Rights To Roche's Flivas
This article was originally published in PharmAsia News
Executive Summary
Asahi Kasei Pharma signed a licensing agreement with Roche Diagnostics and obtained all intellectual property rights related to Flivas (naftopidil), a drug indicated to treat urination difficulty associated with benign prostate hyperplasia. The company obtained naftopidil's Japanese domestic marketing right in 1999 and current annual sales are ¥11.5 billion. With a strategic focus on urology drug business, Asahi Kasei Pharma also aims to expand to overseas markets. (Click here for more - Japanese language) "Asahi Kasei Pharma Obtains All Intellectual Property Rights To BPH Drug From German Company" - Nikkei Sangyo News (11/18/08)